Bharat Biotech to acquire GSK's Indian vaccine firm for undisclosed sum

Target company is a single-product vaccine maker with an installed capacity of 15 million doses of anti-rabies vaccine a year; revenues were Rs 180 cr last year

Hyderabad-based vaccine maker Bharat Biotech today announced that it has signed a definitive agreement to acquire Chiron Behring Vaccines Private Limited (CBVPL) from GlaxoSmithKline(GSK) Asia for an undisclosed sum.

"Bharat Biotech will acquire 100 per cent equity stake in Chiron Behring Vaccines in an all-cash transaction, subject to a number of closing conditions which Bharat Biotech and GSK intend to complete in the coming weeks," it said.

Ankleshwar, Gujarat-based CBVPL is a single product vaccine manufacturing company, which has an installed capacity to produce 15 million doses of anti-rabies vaccine per year. Its revenues stood at Rs 180 crore last